Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Management of Neonates Born to Mothers With Graves’ Disease
source: Pediatrics
year: 2016
authors: Van Der Kaay DC, Wasserman JD, Palmert MR
summary/abstract:Neonates born to mothers with Graves’ disease are at risk for significant morbidity and mortality and need to be appropriately identified and managed. Because no consensus guidelines regarding the treatment of these newborns exist, we sought to generate a literature-based management algorithm. The suggestions include the following:
• Base initial risk assessment on maternal thyroid stimulating hormone (TSH) receptor antibodies. If levels are negative, no specific neonatal follow-up is necessary; if unavailable or positive, regard the newborn as “at risk” for the development of hyperthyroidism.
• Determine levels of TSH-receptor antibodies in cord blood, or as soon as possible thereafter, so that newborns with negative antibodies can be discharged from follow-up.
• Measurement of cord TSH and fT4 levels is not indicated.
• Perform fT4 and TSH levels at day 3 to 5 of life, repeat at day 10 to 14 of life and follow clinically until 2 to 3 months of life.
• Use the same testing schedule in neonates born to mothers with treated or untreated Graves’ disease.
• When warranted, use methimazole (MMI) as the treatment of choice; β-blockers can be added for sympathetic hyperactivity. In refractory cases, potassium iodide may be used in conjunction with MMI. The need for treatment of asymptomatic infants with biochemical hyperthyroidism is uncertain.
• Assess the MMI-treated newborn on a weekly basis until stable, then every 1 to 2 weeks, with a decrease of MMI (and other medications) as tolerated. MMI treatment duration is most commonly 1 to 2 months.
• Be cognizant that central or primary hypothyroidism can occur in these newborns.
DOI: 10.1542/peds.2015-1878
read more full text
myBinderRelated Content
-
Avoiding Grave Cardiac Outcomes in an Athlete with Grave’s DiseaseHistory: A 20-yr male college football ...
-
Teprotumumab for the Treatment of Active Thyroid Eye DiseaseBackground: Thyroid eye disease is a de...
-
Raymond Douglas, MD, PhDDr. Raymond Douglas is the Director of t...
-
Substituting Potassium Iodide for Methimazole as the Treatment for Graves’ Disease During the First Trimester ...Background: To control hyperthyroidism ...
-
Students and Graves’Watching a child undergo dramatic physic...
-
Comparative Effectiveness of Treatment Choices for Graves’ Hyperthyroidism: A Historical Cohort StudyBackground: The optimum therapy for Gra...
-
Left Ventricular Functions in Children With Newly Diagnosed Graves’ Disease: A Single-Center Study From Upper ...This study aimed to evaluate the left ve...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google